Research ExplorerPublicationsEffect of pathological high-risk features on cancer-specific...

Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy

Standard

Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. / Bandini, Marco; Smith, Ariane; Zaffuto, Emanuele; Pompe, Raisa S; Marchioni, Michele; Capitanio, Umberto; Chun, Felix K; Kapoor, Anil B; Shariat, Shahrokh F; Montorsi, Francesco; Briganti, Alberto; Karakiewicz, Pierre I.

In: WORLD J UROL, Vol. 36, No. 1, 01.2018, p. 51-57.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bandini, M, Smith, A, Zaffuto, E, Pompe, RS, Marchioni, M, Capitanio, U, Chun, FK, Kapoor, AB, Shariat, SF, Montorsi, F, Briganti, A & Karakiewicz, PI 2018, 'Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy', WORLD J UROL, vol. 36, no. 1, pp. 51-57. https://doi.org/10.1007/s00345-017-2093-6

APA

Bandini, M., Smith, A., Zaffuto, E., Pompe, R. S., Marchioni, M., Capitanio, U., Chun, F. K., Kapoor, A. B., Shariat, S. F., Montorsi, F., Briganti, A., & Karakiewicz, P. I. (2018). Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. WORLD J UROL, 36(1), 51-57. https://doi.org/10.1007/s00345-017-2093-6

Vancouver

Bandini M, Smith A, Zaffuto E, Pompe RS, Marchioni M, Capitanio U et al. Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. WORLD J UROL. 2018 Jan;36(1):51-57. https://doi.org/10.1007/s00345-017-2093-6

Bibtex

@article{843a582a1da84389b3e54aa9cab8e0d3,
title = "Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy",
abstract = "PURPOSE: Adjuvant therapies for non-metastatic renal cell carcinoma (nmRCC) are being tested to improve outcomes in patients with high-risk (hR) nmRCC. The objective of the current study is to test the ability of three hR features to identify patients who are at the highest risk of cancer-specific mortality (CSM) after partial or radical nephrectomy.METHODS: Within the Surveillance Epidemiology and End Results (SEER) database (1988-2013), we identified 23,632 nm {"}clear cell{"} RCC partial or radical nephrectomy patients with hR features: Fuhrman grade (FG) 3 or 4 or pathological classifications T3a or T3b or lymph node invasion (LNI), or combination of these. Kaplan-Meier analyses (KM) and multivariable Cox's regression models (CRM) evaluated the effect of hR features on CSM.RESULTS: Overall 11,568 (48.9%) patients harbored FG3-4, 5575 (23.6%) pT3a/b, 140 (0.6%) LNI, 5366 (22.7%) FG3-4 and pT3a/b, 183 (0.8%) LNI and pT3a/b, 203 (0.9%) LNI and FG3-4 and 597 (2.5%) LNI, FG3-4 and pT3a/b. Median CSM-free survival was 51, 58 and 22 months for LNI and pT3a/b, for LNI and FG3-4 and for LNI, FG3-4 and pT3a/b and was not reached for the other groups. These results remained unchanged in multivariable CRMs, where all hR features represented independent predictors.CONCLUSIONS: Individuals with combination of LNI with FG3-4 or pT3a/b and patients with all three hR features are at highest risk of CSM. In consequence, these patients may represent ideal candidates for adjuvant therapy either in clinical practice or future prospective trials.",
keywords = "Journal Article",
author = "Marco Bandini and Ariane Smith and Emanuele Zaffuto and Pompe, {Raisa S} and Michele Marchioni and Umberto Capitanio and Chun, {Felix K} and Kapoor, {Anil B} and Shariat, {Shahrokh F} and Francesco Montorsi and Alberto Briganti and Karakiewicz, {Pierre I}",
year = "2018",
month = jan,
doi = "10.1007/s00345-017-2093-6",
language = "English",
volume = "36",
pages = "51--57",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy

AU - Bandini, Marco

AU - Smith, Ariane

AU - Zaffuto, Emanuele

AU - Pompe, Raisa S

AU - Marchioni, Michele

AU - Capitanio, Umberto

AU - Chun, Felix K

AU - Kapoor, Anil B

AU - Shariat, Shahrokh F

AU - Montorsi, Francesco

AU - Briganti, Alberto

AU - Karakiewicz, Pierre I

PY - 2018/1

Y1 - 2018/1

N2 - PURPOSE: Adjuvant therapies for non-metastatic renal cell carcinoma (nmRCC) are being tested to improve outcomes in patients with high-risk (hR) nmRCC. The objective of the current study is to test the ability of three hR features to identify patients who are at the highest risk of cancer-specific mortality (CSM) after partial or radical nephrectomy.METHODS: Within the Surveillance Epidemiology and End Results (SEER) database (1988-2013), we identified 23,632 nm "clear cell" RCC partial or radical nephrectomy patients with hR features: Fuhrman grade (FG) 3 or 4 or pathological classifications T3a or T3b or lymph node invasion (LNI), or combination of these. Kaplan-Meier analyses (KM) and multivariable Cox's regression models (CRM) evaluated the effect of hR features on CSM.RESULTS: Overall 11,568 (48.9%) patients harbored FG3-4, 5575 (23.6%) pT3a/b, 140 (0.6%) LNI, 5366 (22.7%) FG3-4 and pT3a/b, 183 (0.8%) LNI and pT3a/b, 203 (0.9%) LNI and FG3-4 and 597 (2.5%) LNI, FG3-4 and pT3a/b. Median CSM-free survival was 51, 58 and 22 months for LNI and pT3a/b, for LNI and FG3-4 and for LNI, FG3-4 and pT3a/b and was not reached for the other groups. These results remained unchanged in multivariable CRMs, where all hR features represented independent predictors.CONCLUSIONS: Individuals with combination of LNI with FG3-4 or pT3a/b and patients with all three hR features are at highest risk of CSM. In consequence, these patients may represent ideal candidates for adjuvant therapy either in clinical practice or future prospective trials.

AB - PURPOSE: Adjuvant therapies for non-metastatic renal cell carcinoma (nmRCC) are being tested to improve outcomes in patients with high-risk (hR) nmRCC. The objective of the current study is to test the ability of three hR features to identify patients who are at the highest risk of cancer-specific mortality (CSM) after partial or radical nephrectomy.METHODS: Within the Surveillance Epidemiology and End Results (SEER) database (1988-2013), we identified 23,632 nm "clear cell" RCC partial or radical nephrectomy patients with hR features: Fuhrman grade (FG) 3 or 4 or pathological classifications T3a or T3b or lymph node invasion (LNI), or combination of these. Kaplan-Meier analyses (KM) and multivariable Cox's regression models (CRM) evaluated the effect of hR features on CSM.RESULTS: Overall 11,568 (48.9%) patients harbored FG3-4, 5575 (23.6%) pT3a/b, 140 (0.6%) LNI, 5366 (22.7%) FG3-4 and pT3a/b, 183 (0.8%) LNI and pT3a/b, 203 (0.9%) LNI and FG3-4 and 597 (2.5%) LNI, FG3-4 and pT3a/b. Median CSM-free survival was 51, 58 and 22 months for LNI and pT3a/b, for LNI and FG3-4 and for LNI, FG3-4 and pT3a/b and was not reached for the other groups. These results remained unchanged in multivariable CRMs, where all hR features represented independent predictors.CONCLUSIONS: Individuals with combination of LNI with FG3-4 or pT3a/b and patients with all three hR features are at highest risk of CSM. In consequence, these patients may represent ideal candidates for adjuvant therapy either in clinical practice or future prospective trials.

KW - Journal Article

U2 - 10.1007/s00345-017-2093-6

DO - 10.1007/s00345-017-2093-6

M3 - SCORING: Journal article

C2 - 29022072

VL - 36

SP - 51

EP - 57

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 1

ER -